Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC
Osimertinib in adjuvant, now after chemotherapy and radiation, next… Neoadjuvant??? Trials are ongoing.
This is here till progression.
Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study
Author(s): Silvia Novello, MD, PhD1; Dariusz M. Kowalski, MD, PhD2; Alexander Luft, MD, PhD3; Mahmut Gümüş, MD4; David Vicente, MD5; Julien Mazières, MD, PhD6; Jeronimo Rodríguez-Cid, MD7; Ali Tafreshi, MD8; Ying Cheng, MD9; Ki Hyeong Lee, MD, PhD10; Alexander Golf, MD11; Shunichi Sugawara, MD, PhD12; Andrew G. Robinson, MD13; Balazs Halmos, MD14; Erin Jensen, MS15; Paul Schwarzenberger, MD16; M. Catherine Pietanza, MD16; and Luis Paz-Ares, MD, PhD17
Source: DOI: 10.1200/JCO.22.01990 Journal of Clinical Oncology 41, no. 11 (April 10, 2023) 1999-2006.
Dr. Maen Hussein's Thoughts
Three trial updates confirm what we already know and practice.
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.
We report 5-year efficacy and safety outcomes from the phase III KEYNOTE-407 study (ClinicalTrials.gov identifier: NCT02775435). Eligible patients with previously untreated, metastatic squamous non–small-cell lung cancer (NSCLC) were randomly assigned 1:1 to pembrolizumab 200 mg or placebo plus carboplatin and paclitaxel/nab-paclitaxel once every 3 weeks for four cycles, followed by pembrolizumab or placebo for up to 35 cycles. Primary end points were overall survival (OS) and progression-free survival (PFS) per RECIST version 1.1 by blinded independent central review (BICR). Five hundred fifty-nine patients were randomly assigned in the intention-to-treat population (pembrolizumab plus chemotherapy, n = 278; placebo plus chemotherapy, n = 281). The median time from random assignment to data cutoff was 56.9 (range, 49.9-66.2) months. OS and PFS were improved with pembrolizumab plus chemotherapy versus placebo plus chemotherapy (hazard ratio [95% CI], 0.71 [0.59 to 0.85] and 0.62 [0.52 to 0.74]), with 5-year OS rates of 18.4% versus 9.7%, respectively. Toxicity was manageable. Among 55 patients who completed 35 cycles of pembrolizumab, the objective response rate was 90.9% and the 3-year OS rate after completion of 35 cycles (approximately 5 years after random assignment) was 69.5%. Pembrolizumab plus chemotherapy maintained an OS and PFS benefit versus placebo plus chemotherapy in previously untreated, metastatic squamous NSCLC and is a standard-of-care first-line treatment option for metastatic squamous NSCLC regardless of programmed death ligand 1 expression.
Author Affiliations
1Department of Oncology, University of Turin, Azienda Ospedaliero Universitaria San Luigi, Turin, Italy2Department of Lung Cancer and Thoracic Tumours, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland3Department of Oncology No. 1 (Thoracic Surgery), Leningrad Regional Clinical Hospital, Saint Petersburg, Russia4Faculty of Medicine, Istanbul Medeniyet University, Istanbul, Turkey5Department of Medical Oncology, Hospital Universitario Virgen Macarena, Sevilla, Spain6Thoracic Oncology, Hôpital Larrey, Centre Hospitalier Universitaire Toulouse, Toulouse, France7Oncology Center, Medica Sur Hospital, Mexico City, Mexico8Wollongong Private Hospital and Wollongong Oncology, Wollongong, NSW, Australia9Department of Oncology, Jilin Cancer Hospital, Changchun, China10Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheong-ju, South Korea11Medical Oncology, Universitätskinikum Tübingen, Tuebingen, Germany12Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Miyagi, Japan13Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, ON, Canada14Montefiore Medical Center/Albert Einstein College of Medicine, The Bronx, NY15Biostatistics and Research Decision Sciences, Merck & Co, Inc, Rahway, NJ16Global Clinical Development, Merck & Co, Inc, Rahway, NJ17Department of Medical Oncology, Hospital Universitario 12 de Octubre, H12O-CNIO Lung Cancer Unit, Universidad Complutense & Ciberonc, Madrid, SpainRelated Articles
Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC
Another possible option for first line NSCLC EGFR mutated (non-exon 20) is Osimertinib (osi). Osi and chemotherapy had less brain metastases. And with Amivantamab and Lazertinib (EGFR inhibitor), the combination had better PFS and OS (HR0.8). Higher toxicity though with 10% discontinuation vs 3% for Osimertinib. This is interim analysis, toxicity was EGFR related mostly.
Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC
Osimertinib resulted in a significant progression-free survival benefit as compared with placebo: the median progression-free survival was 39.1 months with osimertinib versus 5.6 months with placebo in the EGFR mutated patients. Osmiertinib shows efficacy in patients with EGFR mutation who underwent curative surgery or chemoradiotherapy.
Perioperative Nivolumab in Resectable Lung Cancer
Perioperative nivolumab (Nivo) showed a 20% 18-month EFPS improvement. This is another option to consider for your patients with stage IIA-IIIB NSCLC. Of note, the study arm received chemo + Nivo x 4 cycles preoperatively, then 12 months of Nivo therapy, and toxicities were as expected.
Plasma Proteome–Based Test for First-Line Treatment Selection in Metastatic Non–Small Cell Lung Cancer
FCS medical oncologist and hematologist Ernesto Bustinza-Linares, MD has co-authored an abstract published in the American Society of Clinical Oncology Journal, JCO Precision Oncology, that uncovers a new testing method to determine personalized care options for patients with metastatic non-small cell lung cancer (NSCLC). The abstract’s authors address the limitations of existing guidelines that recommend checkpoint immunotherapy, sometimes in combination with chemotherapy, for treating NSCLC, which often discounts patient variability and immune factors. The findings from the study show that by incorporating additional plasma proteome-based testing, combined with the standard protein inhibitor testing, clear differences in patient outcomes were observed after applying targeted treatments based on the testing results.
